Needham analyst Mike Matson reiterated a Hold rating on Zimmer Biomet (NYSE: ZBH).The analyst commented: "ZBH's 2Q26 revenue and EPS ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments